Risk Factors of Rhino Orbital Mucormycosis

Yugandhara Patade 1, Rashmi G 1

1. Ophthalmology, Sri Devaraj Urs Academy of Higher Education and Research, Kolar, IND

Corresponding author: Rashmi G, dr.rashmi248@gmail.com

Abstract

Purpose: To determine the clinical presentation and risk factors associated with rhino orbital mucormycosis.

Introduction: Mucormycosis is a rapidly progressive fungal infection caused by filamentous fungi in the Mucoraceae family. These fungi develop rapidly, releasing large numbers of spores into the air to which human beings are often exposed through inhalation [1,2]. These fungal hyphae are angioinvasive, causing necrotizing vacuities and thrombosis, resulting in tissue infarcts and necrosis [3]. The COVID-19 infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may range from mild disease to life-threatening conditions, including Mucormycosis, and it has been observed to be one of the most common associations recently [4]. The pandemic of COVID-19 has witnessed a surge in cases of rhino-orbital Mucormycosis [1]. In the last few years, diabetes mellitus and renal diseases have been the common predisposing factors for mucormycosis [5]. Extensive use of corticosteroids, broad-spectrum antibiotics, and monoclonal antibodies may lead to the development of fungal disease or its exacerbation [4]. The most common underlying illnesses of rhino orbital cerebral mucormycosis are diabetes mellitus, hematological malignancies, hematopoietic stem cell transplantation, and solid organ transplantation [6]. Early diagnosis with the initiation of appropriate therapy can save both sight and life [1]. This study is aimed to assess the risk factors and presentation of patients with rhino orbital mucormycosis.

Materials And Methods

Introduction

Mucormycosis is a rapidly progressive fungal infection caused by filamentous fungi in the mucoraceae family. They are ubiquitous, mainly in soil, and occur naturally in the environment, body surfaces, and orifices [1,2]. These fungi develop rapidly, releasing large numbers of spores into the air to which human beings are often exposed through inhalation [1,2]. The spores inoculate in the paranasal sinuses and the nasopharynx. Subsequently, the spread to orbit and intracranial cavity in people with decreased immunity is seen [1,2]. These fungal hyphae are angioinvasive, causing necrotizing vacuities and thrombosis, resulting in tissue infarcts and necrosis [3].

Results: Forty participants were included, out of which 34 (85%) were males and six (15%) were females. The mean age of the patients was 51.75 years. Out of 40 patients, 29 (72.5%) had h/o COVID-19 infection, 30 (75%) were known type 2 diabetes mellitus, 25 (62.5%) had a h/o steroid intake and 25 (62.5%) had a history of O2 use. 17 (42.5%) patients presented with low vision, out of which 15 had no light perception. 30 (75%) were known type 2 diabetes mellitus, 25 (62.5%) had a h/o steroid intake and 25 (62.5%) had a history of O2 use. 17 (42.5%) patients presented with low vision, out of which 15 had no light perception. 30 (75%) patients had ptosis, 22 (55%) patients presented with proptosis, 15 (37.5%) patients had limited ocular motility, 11 (27.5%) had complete ophthalmoplegia, and 11 (27.5%) patients had central retinal artery occlusion.

Conclusion: Rhino orbital Mucormycosis is more prevalent in patients with COVID-19 infection, especially those who have used steroids and oxygen and with type 2 diabetes mellitus. Early presentation with treatment can prevent further ocular morbidity.
This was a prospective, single-center, cross-sectional study conducted at a tertiary care center from June 2021 to July 2022 during the second wave of the COVID-19 pandemic. The predominant strain was delta variant B.1.617. All the patients with microscopically confirmed mucormycosis were included in the study. The samples were obtained through nasal tissue biopsy and stained with potassium hydroxide (KOH). A total of 40 patients diagnosed with rhino orbital mucormycosis in the age group of 18 to 80 years were enrolled, and patients with bacterial infections were excluded from the study. Informed consent was obtained from all the patients included in the study, and Institutional Ethics committee approval was obtained. All the patients were evaluated with a detailed history including sociodemographic profile, occupation, COVID-19 infection, steroid use for more than three months or less than three months, use of immunosuppressants, any organ transplants, any chronic disease or disorder, use of oxygen mask for any health condition, history of prolonged hospital stay, recent or past history of surgeries. A complete ophthalmic evaluation was done, including best-corrected visual acuity, extraocular motility, pupillary reaction, slit lamp biomicroscopy for anterior segment evaluation, and posterior segment evaluation using indirect ophthalmoscopy. Patients underwent blood investigations, including complete blood count, erythrocyte sedimentation rate, C reactive protein, renal function test, liver function test, random blood sugar, D-dimer levels, and serum electrolytes. CT scan of paranasal sinuses, orbit, and brain was done for all the cases and MRI for a few patients as per indications. Mucormycosis was diagnosed based on the demonstration of broad aseptate hyphae with right-angled branching on 20% Potassium hydroxide (KOH) obtained from nasal cavity or paranasal sinuses specimens. All the patients received intravenous liposomal amphotericin B with a dosage of 3-5mg/kg body weight per day. Patients with sinus involvement were taken up for nasal endoscopic debridement, and specimens were sent for microbiology and histopathology by the department of otorhinolaryngology. Orbital debridement and exenteration were considered in patients with necrosis of orbital tissues without a perception of light.

Statistical analysis
Data were entered into a Microsoft Excel data sheet and analyzed using SPSS 22 version software (IBM SPSS Statistics, Somers, NY, USA). Mean-qualitative or categorical data by frequency and percentage presented all quantitative measures.

Results
The study included a total of 40 patients diagnosed with rhino orbital mucormycosis. The mean age of the patients was 51.75 years. Out of 40 patients, 34 (85%) were males, and six (15%) were females (Table 1). Out of 40 patients, 29 (72.5%) patients were COVID-19 positive, 30 (75%) patients were associated with type II diabetes mellitus, 25 (62.5%) patients had received corticosteroids, and 25 (62.5%) had a history of usage (Table 2). Seventeen (42.5%) patients presented with low vision, of which 15 had no perception of light (PL) (Table 3).

<table>
<thead>
<tr>
<th>Gender</th>
<th>Males (%)</th>
<th>Females (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>34 (85)</td>
<td>06 (15)</td>
</tr>
</tbody>
</table>

TABLE 1: Demographic profile of patients with rhino orbital mucormycosis

<table>
<thead>
<tr>
<th>Risk factors</th>
<th>Number of patients (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 infection</td>
<td>29 (72.5)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>30 (75)</td>
</tr>
<tr>
<td>Oxygen usage</td>
<td>25 (62.5)</td>
</tr>
<tr>
<td>Corticosteroids treatment</td>
<td>25 (62.5)</td>
</tr>
</tbody>
</table>

TABLE 2: Risk factors of rhino orbital mucormycosis among diagnosed patients
### TABLE 3: Visual acuity in all the patients diagnosed with rhino orbital mucormycosis

<table>
<thead>
<tr>
<th>Visual acuity</th>
<th>Number (percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/6 to 6/18</td>
<td>8 (20)</td>
</tr>
<tr>
<td>&lt;6/18 to 6/60</td>
<td>8 (20)</td>
</tr>
<tr>
<td>&lt;6/60 to 3/60</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>&lt;3/60 to Perception of Light (PL) +</td>
<td>2 (5)</td>
</tr>
<tr>
<td>No PL</td>
<td>15 (37.5)</td>
</tr>
</tbody>
</table>

PL: perception of light

The most common ophthalmic clinical presentation (Table 4) of these patients was ptosis in 30 (75%) patients (Fig 1), 22 (55%) patients presented with proptosis (Fig 2), 19 patients (47.5%) had chemosis (Fig 2), 15 (37.5%) patients had limited ocular motility, 11 (27.5%) had complete ophthalmoplegia (Fig 3), and 11 (27.5%) patients had central retinal artery occlusion.

### TABLE 4: Clinical features of patients diagnosed with rhino orbital mucormycosis

<table>
<thead>
<tr>
<th>CLINICAL FEATURES</th>
<th>NUMBER OF PATIENTS (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lid edema</td>
<td>33 (82.5)</td>
</tr>
<tr>
<td>Congestion</td>
<td>14 (35)</td>
</tr>
<tr>
<td>Chemosis</td>
<td>19 (47.5)</td>
</tr>
<tr>
<td>Limited ocular motility</td>
<td>15 (37.5)</td>
</tr>
<tr>
<td>Complete ophthalmoplegia</td>
<td>11 (27.5)</td>
</tr>
<tr>
<td>Ptosis</td>
<td>30 (75)</td>
</tr>
<tr>
<td>Proptosis</td>
<td>22 (55)</td>
</tr>
<tr>
<td>Central retinal artery occlusion</td>
<td>11 (27.5)</td>
</tr>
</tbody>
</table>
FIGURE 1: Patient showing complete unilateral ptosis.

FIGURE 2: Patient with unilateral chemosis
which was similar to the other study results. Necrosis factor α (TNF-α) [2]. In our study, 72.5% of patients had a present or history of COVID-19 infection, followed by the use of oxygen mask (62.5%) and steroids treatment (62.5%). The most common presentation in these patients included lid edema, congestion, chemosis, limited ocular motility, complete ophthalmoplegia, ptosis, proptosis, and central retinal artery occlusion.

The most common presentation in these patients included lid edema, congestion, chemosis, limited ocular motility, complete ophthalmoplegia, ptosis, proptosis, and central retinal artery occlusion, which were similar to the study done by Bayram et al., except endophthalmitis which was detected in 54.5% of patients. We did not find any endophthalmitis cases in our study [2]. The demographic profile of the patients in this study was similar to those observed in the literature [13].

In our study, the most commonly prevalent underlying risk factor was diabetes mellitus (75%). This could be due to the ketone reductase enzyme in the Mucorales, which thrive in hyperglycemia and diabetic ketoacidosis. In patients with COVID-19, a patient can develop diabetes mellitus or worsening hyperglycemia in already known diabetic patients due to damage to the β cells and reduced insulin secretion endogenously. Corticosteroids can further worsen glucose control and lead to immune system dysregulation, thereby predisposing to mucormycosis [14]. In these patients, corticosteroids were discontinued immediately, and either insulin therapy or oral hypoglycemic agents controlled blood sugars.

Although there is no direct relationship between COVID-19 disease and Mucormycosis, there was a sudden increase in Mucormycosis cases during the second wave of the COVID-19 pandemic. This could be due to immune dysregulation with a reduction of several T lymphocytes, CD4+ T, CD8+ T cells, and higher proinflammatory cytokines like interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) [2]. In our study, 72.5% of patients had a present or history of COVID-19 infection, which was similar to the other study results [1,2]. However, 27.5% of patients were negative for COVID-19 infection, but 17.5% of patients were associated with diabetes mellitus, 7.5% were on corticosteroids, and...
10% were negative for COVID-19 infection as well as diabetes mellitus. These suggest that other unknown mechanisms play a role in developing mucormycosis, which needs further studies.

The other risk factors associated with mucormycosis were hematological malignancies, previous organ transplantation, immunosuppressive therapy, desferoxamine therapy, and patients on hemodialysis [13,15-18]. Our study did not find an association with any of these risk factors. A well-planned and early diagnosis with a multidisciplinary approach can help save life and sight of the patients. Over the years, microbiological diagnosis, controlling associated systemic conditions, medical treatment, and surgical debridement of necrotic tissue have been the mainstay of treatment of Mucormycosis.

All the patients in our study received systemic liposomal amphotericin B, the first-line drug in the treatment of mucormycosis. It is less toxic and more effective without side effects. Due to vascular thrombosis and necrosis of tissues, amphotericin B may not reach an adequate concentration. Therefore, necrotic and infective tissue debridement is paramount for the antifungals to be effective.

The fungal infection can spread intracranially through the orbital apex, increasing morbidity and mortality. In our study, 7.5% of patients had intracranial involvement, and one underwent exenteration. There needs to be a clear-cut consensus on when exenteration should be performed. A study done by Hargrove et al. with 292 cases of orbital mucormycosis reported that there is no standard consensus on when exenteration has to be performed. Early diagnosis and immediate treatment with systemic and retrobulbar amphotericin B injections can prevent patients from undergoing exenteration [19].

Limitations

The limitations of our study were the small sample size and follow-up was not done for these patients.

Conclusions

Rhino orbital Mucormycosis is more prevalent in patients with COVID-19 infection, primarily those who have used steroids and oxygen and with type 2 diabetes mellitus. An aggressive multidisciplinary approach is required with a high index of suspicion. Early diagnosis and prompt treatment with amphotericin B and surgical debridement can decrease the severity of rhino orbital Mucormycosis.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, SDUMC issued approval DMC/KLR/IEC/427/2022-23. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References


